Beactica is a company that specializes in fragment-based drug discovery using surface plasmon resonance (SPR) biosensor technology. It utilizes its proprietary methodologies to evaluate the interaction of molecules to generate new small molecule therapeutics. The company develops Lysine-specific demethylase 1 (LSD1/KDM1A), which is a bi-functional epigenetic protein regulating the expression of disease-associated proteins, to treat glioblastoma and other cancers.